Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ERIC 2020 | Identifying novel biomarkers and advancing the classification system in CLL

Andreas Agathangelidis • 29 Sep 2020

ERIC 2020

Chronic Lymphocytic Leukemia Leukemia

Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses the two major goals of current chronic lymphocytic leukemia (CLL) research; identifying novel biomarkers and advancing the current classification system. There has been fruitful research in somatic analysis to identify more CLL biomarkers. By analyzing B-cell receptor stereotypy, specific subgroups with similar immunoglobulin genes have been identified. As unique and specific disease variants at a biological and clinical level are identified, accurate treatment can therefore be administered. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

The interplay between genetic and environmental factors in MBL

Andreas Agathangelidis • 6 Oct 2022

The use of AI for analyzing genetic and molecular data in CLL

Andreas Agathangelidis • 6 Oct 2022

Updates on the ERIC recommendations for immunoglobulin gene sequence analysis in CLL

Andreas Agathangelidis • 6 Oct 2022

Clinical significance of Ig gene mutations in CLL

Andreas Agathangelidis • 6 Oct 2022

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024